Central Lab | Market Size, Share & Growth Report 2024-2034
The Central Lab Market Report is Segmented by Service Type (Clinical Chemistry Testing, Microbiology Testing, Hematology Testing, Immunology Testing, and Molecular Diagnostics), End User (Hospitals, Pharmaceutical Companies, Clinical Research Organizations, Academic & Research Institutes, and Others), Test Type (Routine Tests, Specialized Tests, Esoteric Tests, Endocrinology Tests, Infectious Disease Tests, and Others), Sample Type (Blood, Urine, Saliva, Tissue, and Others).
Central Lab Market
Market Analysis
How the market stands today, and what is shaping it
The global central lab market was estimated at approximately USD 3.46 billion in 2024 and is projected to reach around USD 6.69 billion by 2034, representing a CAGR of approximately 6.82% during 2024–2034, based on Core Market Research estimates. The market supplies centralised testing for clinical trials, covering routine chemistry and haematology safety panels alongside immunoassays, flow cytometry, genomics, anatomic pathology and specialty biomarker work, delivered either directly to sponsors or bundled inside a contract research organisation's development package. Growth is supported by later-phase testing demand, by protocol complexity that writes validated specialty assays into trials, and by consolidation of testing with providers already embedded in successful regulatory submissions. Expansion is constrained by price competition on routine testing that any accredited laboratory can perform, by sample transport windows that limit which regions can participate, and by the subcontract position many laboratories occupy. Competition turns on validated assay breadth, sample logistics and regulatory familiarity rather than on price alone. One provider reported central laboratory revenue growth of 11.1% while its early development line fell 13.5% in the same period.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Central Laboratories revenue grew 11.1% in the most recent reported period while Early Development revenue fell 13.5% in the same business. Demand is concentrating in the later-phase testing that central laboratories perform, rather than in the preclinical and early work alongside it.
- Laboratory services from a single provider supported approximately 85% of the new drugs and therapeutic products approved by the FDA in 2025, including 81% of oncology approvals. Sponsors are consolidating testing with providers already embedded in successful submissions rather than distributing it.
- Regulatory datasets require comparability across sites, and national laboratory methods and reference ranges differ. Routing samples from every investigator site to one facility removes that variation from the trial dataset, which is the reason the service exists rather than an efficiency choice.
- Molecular diagnostics, flow cytometry, genomics and precision medicine assays are increasingly written into protocols. These require validated capability a sponsor cannot easily build or relocate, so protocol complexity itself moves work toward providers holding those assays.
- A 500,000 square foot central laboratory facility is to be built in Indiana with construction beginning later in 2026. Capacity is being added specifically to the central laboratory line at a point when the adjacent early development line is contracting.
Market Challenges
- The stored market of USD 3.46 billion for 2024 is close to the USD 3,098.2 million that one provider reported for its whole biopharma laboratory segment in 2025. That segment includes early development work beyond central laboratories, but the overlap is large enough that the stored figure and the disclosed revenue were not reconcilable.
- Early Development revenue fell 13.5% in the same business where central laboratory revenue grew 11.1%. Providers holding both lines face a contracting business alongside a growing one, which complicates capacity planning and makes segment-level reporting a poor guide to central laboratory demand.
- Much of this market is sold as a subcontract rather than directly. Where a central laboratory is bundled inside a contract research organisation's clinical development package, pricing is set within that larger negotiation and the laboratory has limited independent commercial leverage.
- The model depends on moving biological samples from investigator sites to a distant facility within a validated stability window. Customs handling and transport time therefore determine which regions can participate, independently of local clinical or laboratory capability.
- Routine chemistry and haematology supply the volume but can be performed by any accredited laboratory, so that portion of the work is competed on price and turnaround. Margin depends on esoteric and biomarker testing, which is a much smaller share of samples.
Opportunities
- Precision medicine assays in oncology depend on tissue samples and anatomic pathology, which are among the highest-value tests performed. Growth in biomarker-stratified oncology protocols could raise value per participant without any increase in trial numbers.
- Automating site laboratory workflows may reduce the administrative burden that slows enrolment. A provider that measurably shortens site start-up could compete on trial timelines rather than on assay pricing, which is a different basis from the current contest.
- Regions currently limited by sample transport could be opened by assays validated for longer stability windows or by dried sample formats. That would extend the addressable trial geography rather than the share of existing trials.
- Capacity investment at a time when competitors face a contracting early development line could allow share to be taken in later-phase testing, where demand is currently growing.
- Vaccine and infectious disease programmes require microbiology capability that is not uniformly held. A provider with validated capacity there may be positioned for programmes that periodically surge rather than for steady baseline demand.
Trends and Insights
Key market trends shaping the industry landscape
Late Phase Grows While Early Phase Contracts
High impactShort-termCentral laboratory revenue grew 11.1% in the most recent reported period while early development revenue in the same business fell 13.5%.
Insight: Sponsors appear to be protecting later-stage programmes while cutting discovery and preclinical spend, which favours providers weighted toward central laboratory work over those weighted toward early development.
Testing Is Consolidating Into Few Providers
High impactMid-termOne provider's laboratory services supported approximately 85% of new FDA drug and therapeutic approvals in 2025, and 81% of oncology approvals.
Insight: Concentration is measurable in regulatory outcomes rather than only in revenue share, which suggests sponsors treat provider familiarity with submission requirements as a selection criterion.
Competition Moving to Site Workflow
Medium impactMid-termA major provider launched a workflow automation suite for sponsors and investigator sites in March 2025 rather than a new assay platform.
Insight: Where assay menus have converged, the remaining differentiator is how much administrative load the provider removes from sites, which affects enrolment speed more than data quality.
Capacity Being Built for the Growing Line
Medium impactLong-termA 500,000 square foot central laboratory facility is planned in Indiana with construction beginning later in 2026.
Insight: Physical capacity commitments of that size indicate an expectation that later-phase testing demand persists well beyond the current contract book, which is a stronger signal than guidance alone.
Revenue and Activity Sit in Different Places
Medium impactLong-termTrials increasingly include sites across multiple regions while testing is performed at a small number of facilities.
Insight: Regional trial activity is a poor proxy for regional revenue in this market, which is part of why no provider examined reports central laboratory results by geography.
Segment Analysis
Market segmentation by service type, end user, test type, sample type
These five values do not carry equal commercial weight, and the divide runs between routine chemistry and specialised analysis. Clinical Chemistry Testing and Hematology Testing are the high-volume safety assessments run on nearly every trial participant at every visit, so they supply the base load that makes a central laboratory network viable. Immunology Testing and Molecular Diagnostics are where the differentiation sits, because immunoassays, flow cytometry, genomics and precision medicine assays require capability a sponsor cannot easily replicate or move. Microbiology Testing is the most specialised and the least uniformly required, appearing mainly in infectious disease and vaccine programmes. The commercial pattern is that volume comes from the first group and margin defence from the second, which is why providers describe their specialty biomarker capability rather than their chemistry throughput when competing.
Geography Analysis
Regional market analysis
North America
North America holds the largest concentration of both providers and demand. The largest disclosed central laboratory business is headquartered here, reporting Biopharma Laboratory Services revenue of USD 3,098.2 million for 2025, and a 500,000 square foot central laboratory facility is to be built in Indiana with construction beginning later in 2026. The regulatory pull is also concentrated here: laboratory services from a single provider supported approximately 85% of new drugs and therapeutic products approved by the FDA in 2025, including 81% of oncology approvals. The regional ranking rests on that documented commercial and regulatory concentration rather than on a measured regional market size. No regional market size, share or growth figure was identified for any region in this market, because providers report central laboratory activity as a global service line rather than by geography.
Europe
Europe supplies providers rather than a separately measured market. ICON plc is headquartered in Ireland and delivers laboratory services inside its clinical development portfolio, and Eurofins Scientific is headquartered in Luxembourg with central laboratory operations across the region. The structural point about Europe is regulatory rather than commercial: a trial running across several European countries is exactly the case central laboratories were designed for, because national laboratory reference ranges and methods differ and a single testing facility removes that variation from the dataset. Europe therefore generates demand through trial geography rather than through a distinct regional product. No European market size or growth figure was identified among the sources examined.
Asia Pacific
Asia Pacific matters to this market mainly through where trials are run rather than where laboratories are owned. Central laboratory models require samples to move from investigator sites to a small number of testing facilities within a stable time window, so the region's contribution depends on logistics and on the regulatory acceptability of shipping biological samples across borders. Where a sponsor runs a multi-region trial including Asia Pacific sites, the testing revenue may be recognised in a facility located elsewhere, which means regional activity and regional revenue can diverge substantially. No market size, share or growth figure specific to Asia Pacific was identified, and none of the providers examined discloses central laboratory revenue by region.
Latin America
No market size, revenue or growth figure specific to Latin America was identified for central laboratory services, and no provider examined reports regional results for this line. The region participates as a source of trial sites and therefore of samples rather than as a location of testing capacity among the facilities identified. The consequence is the same divergence described for Asia Pacific: sites in the region generate samples, while the revenue for testing them is recognised wherever the central laboratory sits. Sample transport time and customs handling are the practical constraints on how much trial work a region can support under a central laboratory model, rather than local laboratory capability.
Middle East & Africa
No market size, prescribing or revenue figure specific to the Middle East and Africa was identified for this market, and no provider examined discloses activity there separately. The region's participation in centralised trial testing is limited by the same logistics that govern Latin America and parts of Asia Pacific, since a central laboratory model depends on moving samples to a distant facility within a validated stability window. Where that is not achievable, trials either use local laboratories with the data variability central testing exists to remove, or the region is not included in the trial. This is a structural limit on participation rather than a commercial one.
Competitive Landscape
Key players and market positioning analysis
Competition here divides between providers that sell central laboratory services as a standalone capability and those that bundle them inside a wider clinical development contract, and that distinction matters more than assay menu differences. Labcorp Holdings Inc. is the largest by disclosed revenue, reporting Biopharma Laboratory Services revenue of USD 3,098.2 million for 2025 against USD 2,923 million in 2024, a 6.0% increase, within total company revenue of USD 13,951.7 million. Inside that segment its Central Laboratories line grew 11.1% while Early Development fell 13.5%, and it is building a 500,000 square foot central laboratory facility in Indiana from later in 2026. It also stated that its laboratory services supported approximately 85% of new FDA drug and therapeutic approvals in 2025. IQVIA Holdings Inc. competes through IQVIA Laboratories, which offers central laboratory and specialty biomarker services spanning genomics, immunoassays, flow cytometry, anatomic pathology, precision medicine assays, vaccine assays and bioanalytical work, and which launched Site Lab Navigator in March 2025 to automate site laboratory workflows. Its central laboratory business has operated as Q2 Solutions, a joint venture with Quest Diagnostics. ICON plc supplies laboratory services as part of its clinical development services portfolio rather than as a separate offering, and Thermo Fisher Scientific Inc. competes on the same bundled basis through its clinical research business. Eurofins Scientific SE approaches the market from testing laboratories rather than from clinical research, giving it a different route to the same sponsors. Quest Diagnostics, Charles River Laboratories, Medpace, Frontage and SGS also operate in this market without appearing in the Major Players list. The principal competitive factors are validated assay breadth, the ability to move samples reliably from distributed sites, and familiarity with regulatory submission requirements.
Major Players
Leading companies in the market
Industry Developments
4 recorded developments
Labcorp announced a strategic investment in a 500,000 square foot Central Laboratory facility in Indiana, with construction expected to begin later in 2026. Capacity is being added to the central laboratory line specifically, at a time when the early development line is contracting.
IQVIA Laboratories launched Site Lab Navigator in March 2025, a suite intended to automate and streamline laboratory workflows for trial sponsors and investigator sites. The competitive move was toward reducing site burden rather than toward adding assay capability.
Labcorp reported Biopharma Laboratory Services revenue of USD 3,098.2 million for 2025, up from USD 2,923 million in 2024, a 6.0% increase. Within it, Central Laboratories revenue grew 11.1% while Early Development revenue fell 13.5%, a divergence that separates the two halves of the segment.
Labcorp stated that its laboratory services supported approximately 85% of the new drugs and therapeutic products approved by the FDA in 2025, including 81% of oncology-related approvals. Concentration of trial testing in a few providers is measurable in approval outcomes, not only in revenue.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Service Type
5.3 By End User
5.4 By Test Type
5.5 By Sample Type
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Labcorp Holdings Inc.
9.2 IQVIA Holdings Inc.
9.3 ICON plc
9.4 Thermo Fisher Scientific Inc.
9.5 Eurofins Scientific SE
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2024
Forecast Period: 2024 - 2034
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Labcorp Holdings Inc., IQVIA Holdings Inc., ICON plc, Thermo Fisher Scientific Inc. + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.